

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

In re Entresto (Sacubitril/Valsartan) Patent Litigation	)	C.A. No. 20-md-2930-RGA
	)	
NOVARTIS PHARMACEUTICALS CORPORATION,	)	
Plaintiff,	)	
v.	)	
ALKEM LABORATORIES LTD.,	)	
AUROBINDO PHARMA USA INC.,	)	
AUROBINDO PHARMA LTD., DR.	)	
REDDY'S LABORATORIES, INC., DR.	)	
REDDY'S LABORATORIES, LTD.,	)	C.A. No. 21-1330-RGA
HETERO USA INC., HETERO LABS LIMITED, HETERO LABS LIMITED	)	
UNIT III, LAURUS LABS LIMITED,	)	
LAURUS GENERICS INC.,	)	
MACLEODS PHARMACEUTICALS LTD., MACLEODS PHARMA USA,	)	
INC., TORRENT PHARMA INC.,	)	
TORRENT PHARMACEUTICALS LTD.,	)	
Defendants.	)	
	)	
	)	

**DEFENDANTS' NOTICE OF DEPOSITION OF  
PETER WAIBEL UNDER FED. R. CIV. P. 30(B)(1)**

PLEASE TAKE NOTICE that, pursuant to Fed. R. Civ. P. 30(b)(1), the applicable Local Civil Rules for the United States District Court for the District of Delaware, and the Court's Orders in this case, Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III (collectively, "Hetero"); Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. (collectively, "Macleods"); and Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.

(collectively, “Torrent,” and collectively with Hetero and Macleods, “Defendants”), by and through their respective counsel, will take the deposition upon oral examination of Peter Waibel. The deposition will be held remotely on June 14, 2023 at 9:00 am (ET) or as otherwise may be mutually agreed upon by the parties, before a court reporter, notary public, or other person authorized by law to administer oaths, and will continue from day to day until complete.

The deposition will be conducted in accordance with the Federal Rules of Civil Procedure and applicable Local Rules of the United States District Court for the District of Delaware, and will continue from day to day until completed, with such adjournments as may be necessary. The deposition will be conducted before a Notary Public or other officer authorized to administer oaths and will be recorded by stenographic and/or videographic means. The testimony taken pursuant to this Notice of Deposition may be used for any and all appropriate purposes as provided by the Federal Rules of Civil Procedure and Federal Rules of Evidence.

Dated: June 5, 2023

SMITH, KATZENSTEIN & JENKINS LLP

/s/ April M. Ferraro  
John M. Seaman (No. 3868)  
April M. Ferraro (No. 6152)  
ABRAMS & BAYLISS LLP  
20 Montchanin Road, Suite 200  
Wilmington, DE 19807  
(302) 778-1000  
seaman@abramsbayliss.com  
ferraro@abramsbayliss.com

*Of Counsel:*

A. Neal Seth  
Corey Weinstein  
WILEY  
2050 M St., NW  
Washington, D.C. 20036  
(202) 719-7000  
nseth@wiley.law  
cweinstein@wiley.law

*Attorneys for Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.*

SMITH, KATZENSTEIN & JENKINS LLP

/s/ Daniel A. Taylor  
Neal C. Belgam (No. 2721)  
Daniel A. Taylor (No. 6934)  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
(302) 652-8400  
nbelgam@skjlaw.com  
dtaylor@skjlaw.com

*of Counsel:*

Dmitry V. Shelhoff  
Kenneth S. Canfield  
Edward D. Pergament  
Julia S. Kim  
PERGAMENT & CEPEDA LLP  
25A Hanover Road, Suite 104  
Florham Park, NJ 07932  
(973) 998-7722  
dshelhoff@pergamentcepeda.com  
kcanfield@pergamentcepeda.com  
epergament@pergamentcepeda.com  
jkim@pergamentcepeda.com

*Attorneys for Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.*